ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Clinical trial NCT04602117 · WITHDRAWN

Trial details

NCT number: NCT04602117
Sponsor: QuantumLeap Healthcare Collaborative
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

HER2-positive Breast Cancer HER2 Low SYD-985 SYD985 Vic-trastuzumab Duocarmazine Metastatic Cancer Metastatic Breast Cancer Metastatic Gastrointestinal Carcinoid Tumor Metastatic HER2 Low Breast Cancer GastroEsophageal Cancer Gastroesophageal Adenocarcinoma

Start date: 2021-07-28
Primary completion: 2021-11-17
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.